Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST INDXX FUTURE ECONOMY METALS UCITS ETF 15.10.2026 METL LN IE000UDFKE13  150,002.00 USD   5,244,393.73   34.962  ...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Low Duration Global Government Bond UCITS ETF 15.10.2026 FGOV LN IE00BKS2X200   69,469.00 GBP   1,020,621.56   17.381  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 15.10.2026 SDVI.LN IE000YVOQ2A3   40,361.00 USD   1,140,280.56   28.252  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 15.10.2026 SDVY.LN IE0001R850E1 15,354,007.00 USD 383,542,360.15   24.980  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Growth Strength UCITS ETF 15.10.2026 FTGS.LN IE000YZLMXT9   25,002.00 USD    601,998.47   24.078  ...
-

Westwater Resources Reports Strong Progress in Advancing the Coosa Graphite Mine

GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--Westwater Resources, Inc. (NYSE American: WWR), an energy technology and battery-grade natural graphite company (“Westwater” or the “Company”), today announced continued progress related to the Coosa Graphite Mine (“Coosa”) in Coosa County, Alabama.Coosa is advancing as a covered project under FAST-41, which provides a coordinated and transparent framework for federal environmental review and permitting. Westwater continues to work with participating ag...
-

Estuary Biotherapeutics Launches with $103 Million to Develop Targeted Gene Therapies for Kidney Disease

MENLO PARK, Calif. & NEWTON, Mass.--(BUSINESS WIRE)--Estuary Biotherapeutics, Inc., a biotechnology company developing genetic medicines for patients with serious kidney diseases, today announced its launch with $103 million in total committed financing. The $93 million Series A was led by RA Capital Management and included participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a family office...